Last Updated: June 25, 2026

CLINICAL TRIALS PROFILE FOR TOLVAPTAN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for TOLVAPTAN

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00043758 ↗	Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 2	2002-07-01	The purpose of this study is to study the effects of tolvaptan on the size and function of the left heart chamber (ventricle) in patients with congestive heart failure (CHF)
NCT00043771 ↗	Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 2	2002-05-01	Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.
NCT00071331 ↗	EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3	2003-09-01	The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for TOLVAPTAN

Condition Name

Chart
Table

Condition Name for TOLVAPTAN
Intervention	Trials
Hyponatremia	18
Autosomal Dominant Polycystic Kidney Disease	11
Heart Failure	8
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for TOLVAPTAN
Intervention	Trials
Polycystic Kidney Diseases	29
Polycystic Kidney, Autosomal Dominant	28
Kidney Diseases	27
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for TOLVAPTAN

Trials by Country

Map
Table

Trials by Country for TOLVAPTAN
Location	Trials
United States	372
United Kingdom	43
Germany	28
Canada	23
Australia	20
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for TOLVAPTAN
Location	Trials
Pennsylvania	17
Georgia	17
North Carolina	16
Minnesota	16
Ohio	16
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for TOLVAPTAN

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for TOLVAPTAN
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for TOLVAPTAN
Clinical Trial Phase	Trials
Completed	58
Not yet recruiting	10
Terminated	9
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TOLVAPTAN

Sponsor Name

Chart
Table

Sponsor Name for TOLVAPTAN
Sponsor	Trials
Otsuka Pharmaceutical Development & Commercialization, Inc.	26
Otsuka Pharmaceutical Co., Ltd.	14
Otsuka America Pharmaceutical	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for TOLVAPTAN
Sponsor	Trials
Other	97
Industry	73
U.S. Fed	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.